COVID-19 Vaccines Found Effective in India

The Lancet Regional Health South East recently published the results from a peer-reviewed study that determined the safety and immunogenicity of homologous or heterologous boosters with COVISHIELD™ or COVAXIN® vaccines, which are often used in India.

On January 23, 2023, this study found in the COVISHIELD™ primed group, the seropositivity 28 days post booster in the heterologous COVAXIN® arm was 99% and non-inferior to the homologous COVISHIELD™ arm, which was also 99% (difference 0%; 95% CI: −2.8% to 2.7%).

The study's interpretation wrote homologous and heterologous boosting with COVISHIELD™ or COVAXIN® in COVISHIELD™ or COVAXIN® primed individuals are immunogenic and safe.

And a heterologous boost with COVISHIELD™ after COVAXIN® prime offers the best immune response among the four combinations evaluated.

Funding for this study originated from the Azim Premji Foundation and Bill and Melinda Gates Foundation.

Additionally, the Biological E. Limited CorbeVax® vaccine, based on classical protein subunit vaccine technology, has been deployed in India.

And on January 25, 2023, Bharat Biotech's iNCOVACC® novel replication-deficient adenoviral vector-based was commercially launched. iNCOVACC is an intranasal vaccine that stimulates a broad immune response neutralizing IgG, mucosal IgA, and T cell responses.